MIMEDX Enters Patent License Agreement with Wound Care Competitor
MIMEDX Group, Inc. has reached a settlement with a competitor regarding patent infringement allegations, resulting in a $25 million payment agreement.
Stocks · News reference
Cantor Fitzgerald Reiterates Overweight on MiMedx Group, Maintains $8 Price Target
Cantor Fitzgerald analyst Sarah James reiterates MiMedx Group (NASDAQ:MDXG) with a Overweight and maintains $8 price target.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
MIMEDX Announces Third Quarter 2026 Operating and Financial Results
MIMEDX Group, Inc. reported its financial results for the third quarter of 2026, highlighting a return to positive Adjusted EBITDA and a shift toward a surgical-led business model.
MiMedx, Sanara Receive U.S. Federal Trading Commission Second Request For Additional Information, Documentary Materials For Proposed Business Combination
8-K filing — MIMEDX GROUP, INC. (MDXG)
Filed: 2026-10-16 AccNo: 0001213900-26-110041 Size: 205 KB Item 8.01: Other Events